Cytokinetics, Incorporated (CYTK) is currently Overvalued by 216.50%

Cytokinetics, Incorporated (CYTK) appears overvalued by approximately 216.50% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Downside (live) 216.50% (from live valuation API)
Confidence (live) 8.5/10 (High conviction overvalued)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$85.57

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Cytokinetics, Incorporated overvalued or undervalued?

Based on intrinsic value, Cytokinetics, Incorporated (CYTK) looks priced ahead of a cash-flow-based fair value that blends growth, reinvestment needs, and a risk-adjusted discount rate.

Compared to historical valuation, today’s multiple exceeds the range implied by the company’s own five-year average—suggesting the market is more optimistic than its own past pricing of similar fundamentals.

Market expectations embedded in the price imply a demanding bar for execution: revenue cadence, margin stability, and capital returns would need to accelerate to justify a sustained premium versus fair value.

Key metrics

P/E ratio: 41.3x
Revenue growth (TTM y/y): 4%
Profit margin: 12.3%
Fair value (model): Unlock

Next steps

Frequently asked questions — CYTK

Is CYTK overvalued right now?

Based on our 2026 models, Cytokinetics, Incorporated (CYTK) appears overvalued at $85.57 with roughly 216.5% downside versus fair value. Confirm with valuation ratios and financials before acting.

What is Cytokinetics, Incorporated's intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether CYTK trades above or below fair value. At $85.57, Cytokinetics, Incorporated currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Cytokinetics, Incorporated's intrinsic value calculated?

Tickerplace calculates CYTK's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is CYTK undervalued right now?

A stock is undervalued when price sits below a supportable fair value range. Check whether CYTK's gap aligns with fundamentals using the ratios and financial links on this page.

Peers for CYTK: open their overvalued / undervalued view.

Instant valuation answer